Synergistic Ultrasound Contrast Agent System

A novel system integrating AI, IoT, blockchain, and new materials to create a more efficient, reliable, and quality-controlled ultrasound contrast agent manufacturing process, minimizing the impact of divalent metal cations.

The original patent disclosed improved methods for preparing phospholipid-based ultrasound contrast agents, but it had limitations in terms of formulation optimization, manufacturing process control, and quality verification. The new inventive concept addresses these limitations by incorporating advanced technologies to create a more robust and efficient system.

The synergistic system combines AI-assisted predictive modeling to optimize phospholipid formulations and minimize the impact of divalent metal cations. IoT sensors and machine learning algorithms are used for real-time monitoring of the manufacturing process to detect and prevent precipitation induced by divalent metal cations. A blockchain-based system tracks and verifies the composition and quality of the ultrasound contrast agents, ensuring transparency and trust in the supply chain. Additionally, novel materials with improved stability and resistance to divalent metal cations are fabricated using 3D printing techniques, and computer-implemented simulations predict the behavior of phospholipid-based ultrasound contrast agents in the presence of divalent metal cations.

The new claims introduce a synergistic combination of AI, IoT, blockchain, and new materials to create a more efficient, reliable, and quality-controlled ultrasound contrast agent manufacturing process, which is not obvious from the original patent. The inventive step lies in the integration of these distinct technologies to address the limitations of the original patent.

Alternative embodiments may include the use of different AI algorithms, IoT sensor configurations, or blockchain platforms. Variations may include the application of the synergistic system to other types of contrast agents or medical imaging modalities.

The synergistic ultrasound contrast agent system has significant commercial potential in the medical imaging industry, particularly in the ultrasound market. The system's ability to improve manufacturing efficiency, quality control, and supply chain transparency can lead to increased adoption and revenue growth.